ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0464

Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study

Marco Garrido-Cumbrera1, Helena Marzo-Ortega2, José Correa-Fernández3, Sergio Sanz-Gomez4, Laura Christen5 and Victoria Navarro-Compán6, 1Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, 2The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 3Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, 4Health & Territory Research, Seville, Spain, 5Novartis Pharma AG, Basel, Switzerland, 6Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain

Meeting: ACR Convergence 2020

Keywords: COVID-19, Patient reported outcomes

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Friday, November 6, 2020

Session Title: Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: The COVID-19 pandemic is an unprecedented public health crisis affecting people worldwide, including those with rheumatic and musculoskeletal diseases (RMDS).  REUMAVID aims to assess the impact of the COVID-19 pandemic and lockdown on the wellbeing, mental health, disease activity and function, access to healthcare and treatment, support services, and hopes and fears of people RMDs.

Methods: REUMAVID is an international collaboration led by the Health & Territory Research group at University of Seville, Spain, together with a multidisciplinary team including patient organizations and rheumatologists. The study consists of an online survey gathering data from patients with a diagnosis of 15 RMDs in Cyprus, France, Greece, Italy, Portugal, Spain, and the United Kingdom. Participants are recruited by patient organizations. Data is collected in two phases: 1) during the first peak of the COVID-19 pandemic (Spring 2020), and 2) either during the predicted second peak, or as a follow-up if a second peak does not occur (Fall 2020). This analysis presents preliminary descriptive results of the aggregated data, summarizing continuous and categorical variables.

Results: A total of 1,707 RMD patients have participated in Phase 1 so far (from early April to mid-June 2020). The most frequent reported diagnosis were axial spondyloarthritis (47.5%), 618 (36.2%), rheumatoid arthritis (36.2%) and osteoarthritis (22.0%). Mean age was 50.9±17.1 years, 78.2% were female, 68.8% were in a relationship or married and 28.4% had university studies. In total, 1.4% had tested positive for COVID-19, 11.5% reported symptoms but were not tested, while 87.0% did not experience symptoms. 45.0% reported worsening health during the pandemic. 59.7% perceived their health status to be “fair to very bad” and 52.4% reported poor wellbeing according to the WHO-5 scale. Psychological health during the pandemic was also poor, with 55.3% marking as anxiety and 44.3% as depression in the HADS scale. Access to care was limited with 60.6% being unable to keep the rheumatologist appointment, of which 92.5% were cancelled by the provider.  15.3% changed their medication, for which 60.4% were changed by the provider and 28.1% own decision. Reported wellbeing and psychological health during the pandemic was poor, with 52.4% reporting poor wellbeing according to the WHO-5 scale, 55.3% marking as anxiety and 44.3% as depression in the HADS scale. During the pandemic, 25.0% smoked and 17.2% drank more than before and 42.9% were unable to exercise at home.

Conclusion: Preliminary results show disturbance of the healthcare quality, substantial changes to harmful health behaviors and an unprecedented impairment of mental health in REUMAVID participants. REUMAVID will continue to collect information in order to assess the impact of the COVID-19 pandemic in people affected by RMDs across Europe.


Disclosure: M. Garrido-Cumbrera, None; H. Marzo-Ortega, Novartis, 2, 5, 8, Janssen, 2, 5, 8, Eli Lilly, 5, 8, Pfizer, 5, 8, UCB, 5, 8, AbbVie Inc., 5, 8, Celgene, 5, 8, Takeda Pharmaceutical Company, 5, 8; J. Correa-Fernández, None; S. Sanz-Gomez, None; L. Christen, Novartis Pharma AG, 3; V. Navarro-Compán, Novartis Pharma, 1, 5, 8, AbbVie Inc., 5, 8, Eli Lilly and Company, 5, 8, Pfizer Inc., 5, UCB, 5, 8.

To cite this abstract in AMA style:

Garrido-Cumbrera M, Marzo-Ortega H, Correa-Fernández J, Sanz-Gomez S, Christen L, Navarro-Compán V. Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/assessment-of-the-covid-19-pandemic-from-the-perspective-of-people-with-rheumatic-musculoskeletal-diseases-in-europe-preliminary-results-from-the-reumavid-study/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-covid-19-pandemic-from-the-perspective-of-people-with-rheumatic-musculoskeletal-diseases-in-europe-preliminary-results-from-the-reumavid-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.